- ROUNDTABLE: Pharmacy’s future in sync with technology
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Study from NCPA sheds new light on med synchronization programs
- Senate passes Drug Quality and Security Act
ALEXANDRIA, Va. — The National Association of Specialty Pharmacy will begin developing pharmacy practice parameters in about 20 specialty therapeutic categories this year, the group said.
The NASP said it would engage specialty pharmacists, executives, payers, reimbursement consultants and organizations and patient advocacy groups focused on disease states to develop standards of practice for pharmacists in the targeted therapeutic areas. Parameters also will include information technology and metrics for adherence and outcomes that will allow organizations to use and embellish a set of baseline standards.
"Our goal as an organization is to establish practice standards that encompass clinical guidelines, benefit design and management and information technology to measure adherence and outcomes," NASP CEO Gary Cohen said. "We will collaborate with other stakeholders to utilize existing and emerging guidelines and adapt them to the specific needs of the specialty pharmacy community. Specialty pharmacists are playing a more integral role in the collaborative care model and will be a key driver of successful patient outcomes."
The group said it was recruiting volunteers to work on advisory and consensus groups in different disease categories to support the development of practice parameters.
"All the newly approved specialty pharmaceuticals targeted therapies coming on the market today require highly skilled, specialized pharmacists who have disease and drug-specific training and IT systems to support ongoing concurrent medication treatment management," NASP board member and Onco360 CEO Burt Zweigenhaft said.